Stockscreener 앱 받기
8.99
6.55%
-0.63
시간 외 거래:
8.80
-0.19
-2.11%
전일 마감가:
$9.62
열려 있는:
$9.705
하루 거래량:
341.24K
Relative Volume:
0.54
시가총액:
$486.28M
수익:
$2.81M
순이익/손실:
$-97.34M
주가수익비율:
-5.6899
EPS:
-1.58
순현금흐름:
$-91.47M
1주 성능:
-2.49%
1개월 성능:
+28.61%
6개월 성능:
+242.48%
1년 성능:
+174.92%
1일 변동 폭
$8.99
$9.705
1주일 범위
$8.99
$9.88
52주 변동 폭
$2.315
$9.88
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
FULC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
8.99 | 520.36M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-09-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2023-09-25 | 개시 | Goldman | Neutral |
| 2023-08-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | 업그레이드 | Stifel | Hold → Buy |
| 2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 개시 | Goldman | Buy |
| 2022-03-08 | 개시 | Oppenheimer | Outperform |
| 2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-16 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Detecting price anomalies in Fulcrum Therapeutics Inc. with AIIPO Watch & Low Drawdown Investment Strategies - newser.com
Is Fulcrum Therapeutics Inc. stock poised for growthTrade Volume Report & Safe Entry Zone Identification - newser.com
What moving averages say about Fulcrum Therapeutics Inc.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Order flow analysis tools used on Fulcrum Therapeutics Inc.2025 Short Interest & Daily Profit Focused Screening - newser.com
What data driven models say about Fulcrum Therapeutics Inc.’s future2025 Top Gainers & Fast Moving Stock Trade Plans - newser.com
Can Fulcrum Therapeutics Inc. recover in the next quarterProduct Launch & High Return Stock Watch Alerts - newser.com
Fulcrum Therapeutics Inc. stock momentum explainedQuarterly Profit Report & Fast Gain Swing Trade Alerts - newser.com
Fulcrum Therapeutics (NASDAQ:FULC) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Fulcrum Therapeutics (NASDAQ:FULC) Reaches New 12-Month HighHere's What Happened - MarketBeat
Fulcrum Therapeutics, Inc. $FULC Shares Sold by Matisse Capital - MarketBeat
How supply chain issues affect Fulcrum Therapeutics Inc. stockJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - newser.com
What does recent volatility data suggest for Fulcrum Therapeutics Inc.July 2025 Trends & Community Consensus Picks - newser.com
Technical analysis overview for Fulcrum Therapeutics Inc. stockTrade Ideas & Growth Focused Entry Reports - newser.com
Published on: 2025-10-05 20:19:33 - newser.com
Pattern recognition hints at Fulcrum Therapeutics Inc. upsideJuly 2025 Fed Impact & Stock Portfolio Risk Management - newser.com
Is Fulcrum Therapeutics Inc. stock trading near support levelsRate Cut & Safe Capital Growth Stock Tips - newser.com
Using flow based indicators on Fulcrum Therapeutics Inc.Trade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Fulcrum Therapeutics Inc. recovery potential after sell offInflation Watch & Safe Entry Point Identification - newser.com
What earnings revisions data tells us about Fulcrum Therapeutics Inc.Weekly Stock Report & Fast Moving Stock Watchlists - newser.com
Can Fulcrum Therapeutics Inc. stock sustain market leadershipJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - newser.com
Fulcrum Therapeutics (NASDAQ:FULC) Sets New 52-Week HighTime to Buy? - MarketBeat
Oppenheimer reiterates Outperform on Fulcrum Therapeutics stock ahead of data - Investing.com Canada
What analysts say about Fulcrum Therapeutics Inc stockSwing Trading Watchlist & Set Your Capital Stop-Loss Limits Effectively - earlytimes.in
Fulcrum Therapeutics, MyoKardia end agreement on cardiomyopathy treatments - MSN
Fulcrum Therapeutics (NASDAQ:FULC) Raised to “Hold” at Wall Street Zen - Defense World
Fulcrum Therapeutics (NASDAQ:FULC) Raised to Hold at Wall Street Zen - MarketBeat
Is Fulcrum Therapeutics Inc a good long term investmentResistance Zone Identification & Superior Wealth Building - Early Times
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
5.74%
자본화:
|
볼륨(24시간):